Printer Friendly

CYTOGEN INITIATES CLINICAL TRIALS OF THROMBOSCAN(TM), THE WORLD'S FIRST MRU PRODUCT

 CYTOGEN INITIATES CLINICAL TRIALS OF THROMBOSCAN(TM),
 THE WORLD'S FIRST MRU PRODUCT
 PRINCETON, N.J., Jan. 20 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) reported the initiation of Phase I human clinical trials its the cardiovascular imaging agent using a molecular recognition unit (MRU).
 MRUs are short chains of amino acids that have the ability to bind with specific target sites in the human body. This product, ThromboScan, is designed to detect blood clots in the circulatory system promptly after its injection. This event marks the first time an MRU product has been used in humans.
 The MRU is based on the same targeting principles Cytogen used with monoclonal antibodies to identify cancer cells within the body and deliver an imaging substance. The MRU peptide mimics the performance of a whole antibody, but is only a fraction of its size. In the case of the ThromboScan, the entire MRU is composed of 17 amino acids, in comparison to the 1,320 amino acids of a typical monoclonal antibody. Because this peptide's small size enables it to reach the smallest veins and capillaries of the body, the first product is designed for imaging cardiovascular disease.
 Cytogen Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies in order to optimize the function of the antibody as a delivery vehicle. The company currently has six cancer imaging agents under development and two of these imaging agents, for colorectal and ovarian cancer are awaiting FDA marketing approval. Three cancer therapy agents are also under development.
 /delval/
 -0- 1/20/92
 /CONTACT: Laura M. Hahn of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation ST: New Jersey IN: MTC SU:


JS -- PH001 -- 1298 01/20/92 08:41 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1992
Words:290
Previous Article:CYCLONE AVIATION OF ISRAEL, A HELICOPTER LEADER, PICKS CALIFORNIA INNOVATOR AMERICAN AIRCRAFT CORPORATION
Next Article:SPECIAL DEVICES INC. AUTOMOTIVE PRODUCTS DIVISION RECEIVES TRW AUTHORIZATION
Topics:


Related Articles
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING NON-SMALL CELL LUNG CANCER
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING BREAST CANCER
CYTOGEN ANNOUNCES 1992 ANNUAL MEETING HIGHLIGHTS
CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
FDA APPROVES ONCOSCINT AND INDICLOR FOR COLORECTAL AND OVARIAN CANCER DETECTION; FIRST CANCER IMAGING AGENT BASED ON A MONOCLONAL ANTIBODY
CYTOGEN ACQUIRES RIGHTS TO PAIN RELIEF AGENT FOR BONE CANCER
CYTOGEN ANNOUNCES REVISION OF STRATEGIC PLAN
CYTOGEN CORPORATION ANNOUNCES UPDATE ON SECOND QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
CYTOGEN: FDA APPROVES ONCOSCINT(TM) CR/OV FOR REPEAT ADMINISTRATION
CYTOGEN REPORTS BUSINESS UPDATE AND FIRST QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters